NCT04313400 - Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2020

Primary Completion Date

December 19, 2023

Study Completion Date

January 2, 2024

Conditions

Atopic Dermatitis

Interventions

DRUG

1.1% w/w AMTX-100 CF-part1

AMTX-100 CF, topical cream with 1.1% w/w active pharmaceutical ingredient

DRUG

Placebo

Topical cream manufactured to mimic AMTX-100 CF3

DRUG

1.1% w/w AMTX-100 CF3-part2

AMTX-100 CF3, topical cream with 1.1% w/w active pharmaceutical ingredient

Trial Locations (11)

Amytrx Investigational site, New York

Amytrx Investigational site, Philadelphia

Amytrx Investigational site, Miramar

Amytrx Investigational site, Miami

Amytrx Investigational site, Troy

Amytrx Investigational site, Cerritos

Amytrx Investigational site, Long Beach

Amytrx Investigational site, Sherman Oaks

Amytrx Investigational site, Encino

Amytrx Investigational site, North Hollywood

Amytrx Investigational site, San Diego